Use of Gocovri to Improve Disability Due to Radiation Encephalopathy

Inclusion Criteria: * Individuals ≥ 18 years of age. * Individuals with caregivers who are able to complete survey assessments for this study. * Prior brain radiation treatment. * Evidence of moderate-severe confluent white matter hyperintensity on MRI brain scan as judged by neuroradiology impression 0-5 years prior to enrollment. * DRS \> 6 * The effects of Gocovri on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (e.g. hormonal or barrier method of birth control) prior to study entry and for the duration of study participation; female subjects will be required to demonstrate a negative urine pregnancy test prior to study entry and subjects who are lactating should be excluded. Exclusion Criteria: * Pregnant or breastfeeding. * Patients with growing brain lesions or those requiring escalating doses of tumor-directed treatment.. * Patients requiring doses of Dexamethasone higher than 4 mg or escalating doses of Dexamethasone * Patients taking Amantadine or with prior usage of Amantadine. * Patients taking other dopaminergic, GABAergic, glutamatergic, or noradrenergic drugs. * Patients with a history of suicidality and depression. * Patients with end stage renal disease (creatinine clearance less than 15 mL/min/1.73 m2).